Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, May 5, 2026 to discuss the company’s first quarter financial results.

Investors in Alkermes plc ALKS need to pay close attention to the stock based on moves in the options market lately. That is ...

A Relative Strength Rating upgrade for Alkermes shows improving technical performance. Will it continue?

Label Extension Period Demonstrated Sustained Improvements in Patient-Reported Disease Severity, Cognitive Functioning and ...

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo ...

Alkermes PLC (NASDAQ:ALKS) is one of the 10 Stocks Dominating Today’s Market Surge. Alkermes extended gains for a second day on Tuesday to nearly hit its 52-week high, as investors digested the ...

Detailed price information for Simulations Plus Inc (SLP-Q) from The Globe and Mail including charting and trades.

Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy ...

Alkermes projects total fiscal 2026 revenue between $1.73 billion and $1.84 billion, with net product sales expected to range from $1.52 billion to $1.60 billion. This article was generated with the ...

Alkermes shows rising price performance, earning an upgrade to its IBD Relative Strength Rating ...